AUTOMATED GAS-CHROMATOGRAPHY TANDEM MASS-SPECTROMETRY ASSAY FOR TEBUFELONE AND A C-13, O-18-LABELED ANALOG IN PLASMA - APPLICABILITY TO ABSOLUTE BIOAVAILABILITY DETERMINATION
Rlm. Dobson et al., AUTOMATED GAS-CHROMATOGRAPHY TANDEM MASS-SPECTROMETRY ASSAY FOR TEBUFELONE AND A C-13, O-18-LABELED ANALOG IN PLASMA - APPLICABILITY TO ABSOLUTE BIOAVAILABILITY DETERMINATION, Biological mass spectrometry, 23(2), 1994, pp. 75-81
An automated capillary gas chromatography/tandem mass spectrometry (GC
/MS/MS) assay for the simultaneous quantitation of tebufelone (TE) and
C-13,O-18-labeled TE (TE-CO) in plasma was developed. This method per
mits the use of stable isotope coadministration (TE and TE-CO dosed co
ncurrently via peroral and intravenous routes, respectively) for the d
etermination of TE absolute bioavailability. The selectivity of MS/MS
conducted on a triple-quadrupole instrument allowed minimal sample pre
paration and rapid analysis. Electron ionization produced molecular io
ns (M(+.)) for TE, TE-CO, and the 3-methyl-TE internal standard, which
were selected in Q1 to undergo collisionally activated dissociation i
n Q2. Quantitation was achieved through monitoring product ions at m/z
248, 251, and 248, respectively, in Q3. A 2-1000 ng per sample (40 pg
to 20 ng injected) quantitation range provided access to an effective
1-5000 p.p.b. plasma concentration range (0.2-2 g samples) for both T
E and TE-CO. The assay showed no bias and less than 8% relative standa
rd deviation over the entire range. The method was used to determine p
lasma levels of TE and TE-CO in four dogs receiving 2.5:2.5 mg/kg TE:T
E-CO, intravenously. The pharmacokinetics of both isotopomers proved t
o be identical, indicating no isotope effect and verifying the chemica
l stability of the O-18-carbonyl label under these dosing conditions.
In addition, the applicability of this analytical approach to the dete
rmination of TE peroral bioavailability was initially tested in dogs.